Prosperity7 Ventures Backs Cispoly: A Beacon in China's Gynecological Tumor Detection

In a testament to the thriving Asian startup ecosystem, the Middle East has recently shown increased interest, with significant investments flowing into innovative enterprises.

One notable beneficiary is Cispoly, a China-based pioneer in gynecological tumor detection equipment.

Securing an impressive 100 million yuan (equivalent to US$14 million) in its series B funding round, Cispoly's primary backing came from Prosperity7 Ventures.

This venture arm is affiliated with Saudi Arabia's energy titan, Aramco.

Additionally, Sunland Fund, an existing investor, also contributed to this funding phase.

Founded in 2020 by Liu Pei, Cispoly specializes in developing cutting-edge methylation detection tools tailored for early identification of gynecological tumors.

These tools encompass conditions like cervical cancer, ovarian cancer, and endometrial cancer, along with advanced solutions for women's reproductive microbiota examination.

Highlighting its accomplishments, Cispoly announced that its premier product, Ciscer, received approval from China’s National Medical Products Administration this March.

Further innovations are on the horizon, with products such as Cisendo for endometrial cancer screenings and Cisova for ovarian cancer diagnosis nearing pivotal clinical trial stages.

With the freshly acquired series B capital, Cispoly is strategically positioning itself for expansive growth, emphasizing research and development, global market penetration, and swift product approvals.

Presently, the startup has initiated pivotal research endeavors within China and envisions broader collaborations with medical entities in Southeast Asia and Europe.

For Prosperity7 Ventures, this collaboration with Cispoly marks yet another strategic investment in China's burgeoning healthtech domain.

Previously, the fund showcased its confidence in the sector by supporting Fourier Intelligence, a leader in exoskeleton robotics for rehabilitation exercises, during its series C and D financing rounds.

Additionally, the fund's diverse portfolio boasts significant investments in China's Jiandanxinli, amassing US$28.7 million in a series B initiative, and a notable US$35 million backing for Hong Kong-based Insilico Medicine just last year.

Lokesh Choudhary / Tech in Asia